Brief: Windtree Announces Partnership With New Growth Advisors To Leverage Positive Phase 2 Istaroxime Study In Cardiogenic Shock For A Potential Strategic Transaction

Windtree Therapeutics

04/12/2024 13:55

Dec 4 (Reuters) - Windtree Therapeutics Inc  WINT.O :
    * WINDTREE ANNOUNCES PARTNERSHIP WITH NEW GROWTH ADVISORS TO
LEVERAGE POSITIVE PHASE 2 ISTAROXIME STUDY IN CARDIOGENIC SHOCK
FOR A POTENTIAL STRATEGIC TRANSACTION
    * WINDTREE THERAPEUTICS INC:  ENGAGED NEW GROWTH ADVISORS AS
ITS
STRATEGIC ADVISOR TO LEAD A PROCESS IN RESPECT OF WINDTREE'S
CARDIOVASCULAR PORTFOLIO
    * WINDTREE:  IF A DEAL IS CONSUMMATED FOR CARDIOVASCULAR
PORTFOLIO, PLANS TO USE SOME PROCEEDS TO SUPPORT ADVANCEMENT OF
ONCOLOGY PLATFORM
    * WINDTREE THERAPEUTICS INC - LEE'S PHARMACEUTICALS TO START
PHASE
3 IN ACUTE HEART FAILURE IN H1 2025
    * WINDTREE THERAPEUTICS INC - MAY RECEIVE UP TO $138 MILLION
IN
MILESTONES FROM LEE'S PHARMACEUTICALS

Source text:  ID:nGNXb28vrr 
Further company coverage:  WINT.O 

 ((Reuters.Briefs@thomsonreuters.com;))